1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bio-Techne Corporation

Bio-Techne Corporation

TECH
Bio-Techne CorporationUS flagNASDAQ
72.32
USD
+0.04
- -
11.32BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.11
2.42
3.05
3.35
3.77
4.29
4.72
4.83
6.01
7.05
7.23
7.35
7.74
7.78
Basic EPS, GAAP
0.76
0.75
0.73
0.7
0.51
0.84
0.64
1.5
0.91
1.73
1.81
1.07
0.47
0.7
Free Cash Flow per Basic Share
0.69
0.83
0.81
0.86
0.86
1
1.03
1
1.99
1.79
1.38
1.5
1.63
1.73
Dividend per Share
0.29
0.31
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
Book Value per Share
5.01
5.37
5.7
5.9
6.36
7.17
7.68
8.98
10.03
10.86
12.47
13.08
12.38
13.32
Tangible Book Value per Share
4.16
3.61
1.1
0.93
-0.55
0.23
-0.97
0.89
0.67
2.22
3.55
3.72
3.69
5.04
Basic Weighted Avg Shares
147
148
148
149
149
150
151
153
155
157
157
158
158
156
Sales/Revenue/Turnover
311
358
452
499
563
643
714
739
931
1,106
1,137
1,159
1,220
1,211
Operating Margin (%)
50.32
44.11
33.13
30.38
25.68
24.76
20.6
20.15
26.07
26.76
25.6
21.26
19.91
24.31
Depreciation Expense
12
19
37
43
60
64
78
83
88
101
107
112
110
100
Net Income, GAAP
113
111
108
104
76
126
96
229
140
272
285
168
73
110
Effective Tax Rate (%)
29.94
31.26
30.12
29.16
32.04
- -
14.23
17.07
5.8
12.7
15.71
9.47
25.45
25.54
Profit Margin (%)
36.24
31.01
23.82
20.94
13.51
19.62
13.46
31.04
15.08
24.61
25.1
14.5
6.02
9.05
Working Capital
377
443
209
200
213
319
311
414
358
430
493
458
432
535
LT Debt
- -
7
73
92
344
339
493
411
396
302
444
407
430
276
Total Equity
738
795
847
879
950
1,079
1,166
1,381
1,571
1,701
1,967
2,069
1,919
2,085
Return on Invested Capital (%)
15.2
13.93
12.08
11.3
8.65
- -
8.14
7.07
11.99
12.8
10.98
9.07
7.45
9.11
Return on Capital (%)
15.94
14.36
12.56
11.14
7.15
- -
7.43
14.07
8.11
14.48
13.24
7.43
3.29
4.85
Return on Common Equity (%)
15.94
14.48
13.12
12.1
8.32
12.44
8.56
18.01
9.54
16.67
15.55
8.33
3.68
5.34

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
14
14
14
LT Borrowings
300
260
200
LT Finance Leases
81
77
76
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
156
156
157
Market Capitalization
8,664
9,167
8,180

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
610
637
688
Cash, Cash Equivalents & STI
145
173
210
Accounts Receivable, Net
184
185
215
Inventories
203
205
201
Total Current Liabilities
145
140
153
Payables & Accruals
96
94
99
ST Debt
14
14
14
Deferred Revenue
30
31
38

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.76%
7.12%
-7.25%
Free Cash Flow
11.32%
17.33%
8.66%
Net Income, GAAP
11.29%
-7.51%
-56.34%
Sales/Revenue/Turnover
10.67%
10.96%
5.23%
Total Cash Common Dividend
0.68%
0.6%
-0.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
277
273
303
306
1,159
2025
289
297
316
317
1,220
2026
287
296
311
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
0.17
0.31
0.26
1.07
2025
0.21
0.22
0.14
-0.11
0.47
2026
0.25
0.24
0.33
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.08
0.08
0.08
0.32
2025
0.08
0.08
0.08
0.08
0.32
2026
0.08
0.08
0.08
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kim Kelderman
Full Time Employees
3,100
Sector
Healthcare
Industry
Biotechnology
Address
614 McKinley Place N.E. Minneapolis MN United States of America 55413
IPO Date
Feb 9, 1989
CIK
0000842023
Website
bio-techne.com
Similar Companies
Ab&B Bio-Tech Co. Ltd. JS (2627.HK)
Microbix Biosystems Inc. (MBX.TO)
Polyrizon Ltd. (PLRZ)
Poltreg S.A. (PTG.WA)
ForU Holdings, Inc. (FORU)
ReNeuron Group plc (RENE.L)
Business
Bio-Techne Corporation (NASDAQ: TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and supplies high-quality reagents, analytical instruments, and precision diagnostics for biotechnology research, clinical diagnostics, bioprocessing, and cell and gene therapy applications worldwide; the company operates through two primary segments, Protein Sciences, which provides biological reagents including cytokines, antibodies, immunoassays, cell selection kits, multicolor flow cytometry kits, multiplex assays, biologically active compounds, stem cell products, and proteomic analytical tools, and Diagnostics and Genomics, which offers diagnostic products such as advanced tissue-based in-situ hybridization assays for spatial genomic analysis and tissue biopsy, exosome-based molecular diagnostic assays, controls, calibrators, genetic and oncology kits, and clinical hematology controls; key brands encompass R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, ACD, Asuragen, Lunaphore, and BiosPacific, with over 500,000 products in its catalog, 95% manufactured in-house, supporting customers in pharmaceutical, therapeutic, diagnostics, and life science industries across more than 34 global locations including subsidiaries in Europe, China, and Hong Kong. Founded in 1976 as Research and Diagnostic Systems and renamed Bio-Techne in 2014 following its 1981 incorporation, the company employs over 3,000 people and generated approximately $1.2 billion in net sales for fiscal 2024. Recent developments include a strategic distribution partnership with Spear Bio announced in July 2025 to expand access to SPEAR UltraDetect ultrasensitive immunoassays for neurology biomarkers such as pTau 231, pTau 217, GFAP, and Nf-L, following Bio-Techne's investment in Spear Bio's 2024 Series A funding; the divestiture of its Exosome Diagnostics business to Mdxhealth SA in August 2025 for $15 million plus royalties; licensing of AI-designed NovoBody Duo molecules from Monod Bio in November 2025 to enhance its recombinant protein portfolio; launch of the ProximityScope Assay on the BOND RX platform in October 2025 for spatial protein-protein interactions research; and an AI-powered spatial biology workflow collaboration with Nucleai in November 2025 for predictive biomarker discovery in melanoma patients.

Company News

Company News APIChatGPT

  • gurufocus.com

    TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

  • businesswire.com

    TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

  • defenseworld.net

    BlackRock Inc. Buys Shares of 14,025,816 Bio-Techne Corp $TECH

  • gurufocus.com

    Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders?

  • prnewswire.com

    Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders?

  • zacks.com

    TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises

  • prnewswire.com

    Bio-Techne Corrects Dividend Announcement

  • globenewswire.com

    CMB.TECH ANNOUNCES Q2 2026 RESULTS ON 27/08/2026

  • zacks.com

    Techne (TECH) Q4 Earnings Meet Estimates

  • reuters.com

    Bio-Techne beats revenue estimates on research, diagnostics demand uptick

  • prnewswire.com

    Bio-Techne Releases Fourth Quarter Fiscal 2026 Results

  • prnewswire.com

    Bio-Techne Declares Dividend

  • zacks.com

    JAZZ vs. TECH: Which Stock Is the Better Value Option?

  • defenseworld.net

    California State Teachers Retirement System Grows Holdings in Bio-Techne Corp $TECH

  • globenewswire.com

    CMB.TECH fleet update

  • fool.com

    Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?

  • seekingalpha.com

    Madison Mid Cap Fund Q2 2026 Portfolio Activity

  • seekingalpha.com

    Conestoga SMid Cap Composite Q2 2026 Portfolio Review

  • defenseworld.net

    Bank of Nova Scotia Sells 38,334 Shares of Bio-Techne Corp $TECH

  • zacks.com

    Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?